Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021.
- What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate stable heart failure (HF)? (0.31)
- Could you tell us a little about the RACE-3 study and its findings? (1.50)
- Among the interventions investigated in the study, which appeared to be most and least effective? (3.58)
- What follow-up studies are planned? (4.58)
- Following the results of this study, how do you envision the standard of care developing for patients with AF, with and without HF? (5.35)
Speaker disclosures: Prof. Michiel Rienstra wishes to disclose that RACE 3 was supported by the Netherlands Heart Foundation (Grant 2008B035), and the Netherlands Heart Institute. Further, this trial was funded by unrestricted grants from AstraZeneca, Bayer, Biotronik, Boehringer-Ingelheim, Boston Scientific, Medtronic, Sanofi-Aventis and St-Jude-Medical, paid to the Netherlands Heart Institute. Dr Bao-Oanh Nguyen has nothing to declare in relation to this video interview.
Interview and filming supported by Touch Medical Media. Interview conducted by Heather Hall.
Filmed during a remote video call with Prof. Michiel Rienstra and Dr Bao-Oanh Nguyen as a highlight of EHRA 2021, May 2021
Share this Video
Related Videos In Heart Failure
Roxana Mehran, ESC 2021 – the PARADISE-MI Trial
Dr Roxana Mehran (Director of Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine, Mount Sinai Hospital, New York City, NY, USA) kindly shared her thoughts on the the PARADISE-MI trial (NCT02924727) from from the virtual ESC Congress 2021. Questions What has been the impact of angiotensin receptor-neprilysin inhibitors (ARNIs) on the treatment of […]
Gilles Montalescot, ESC 2021 – the QUORUM Clinical Study
Prof. Gilles Montalescot (Professor, Pitié-Salpêtrière Hospital, Paris, France) kindly shared his thoughts on the difficulty of treating heart failure after acute myocardial infarction, the use of firibastat and the QUORUM clinical study (NCT03715998) from the virtual ESC Congress 2021. Questions Why does heart failure after acute myocardial infarction remain so challenging to treat? (0.19) Could […]
Diana Bonderman, ESC 2021 – the DYNAMIC Study
Prof. Diana Bonderman (Cardiologist, Medical University of Vienna, Vienna, Austria) kindly shared her thoughts on the current challenges in the treatment of pulmonary hypertension and heart failure with preserved ejection fraction, the mechanism and use of riociguat, and the DYNAMIC study (NCT02744339) from from the virtual ESC Congress 2021. Questions What are the challenges in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!